足三里穴位埋线法对阿德福韦酯应答不佳慢性乙型病毒性肝炎患者的影响

The Influence of Acupoint Catgut Embedding in Zusanli on Patients with Chronic Hepatitis B and Poor Response to Adefovir Dipivoxil

目的:观察足三里穴位埋线法对阿德福韦酯应答不佳的慢性乙型病毒性肝炎(乙肝)患者的影响。方法:将符合纳入标准的100例慢性乙肝患者随机分为治疗组和对照组,每组各50例。所有患者在治疗前期均给予阿德福韦酯胶囊治疗,治疗前、治疗24周后予分别测定HBVDNA定量、HBeAg定量和补体C3,把治疗24周后各组中HBV-DNA定量>5×102IU·m L-1的患者(应答不佳)作为各组的研究对象,对照组继续按原治疗方案,治疗组在原治疗方案的基础上给予双侧足三里埋线治疗,24周后再次分别测定两组患者的HBV-DNA定量、HBeAg定量和补体C3。结果:常规治疗24周后两组患者HBV-DNA、HBeAg转阴率比较,差异无统计学意义(P>0.05)。治疗24周后两组患者补体C3都较治疗前升高,但两组间比较,差异无统计学意义(P>0.05)。治疗48周后,治疗组HBV-DNA、HBeAg转阴率和补体C3均低于对照组,差异均有统计学意义(P<0.05)。结论:对于对阿德福韦酯胶囊应答不佳的慢性乙肝患者,双侧足三里埋线治疗可以明显提高HBV-DNA、HBeAg转阴率及补体C3的均值,可明显缩短患者疗程,增加临床疗效。

Objective ： To observe the influence of acupoint catgut embedding in Zusanli （ ST 36） on patients with chronic hepatitis B and poor response to adefovir dipivoxil. Methods： One hundred patients who met the inclusion criteria were randomly divided into the treatment group and the control group, with 50 cases in each group. All the patients were given Adefovir Dipivoxil Capsules in the early treatment stage. Before the treatment and after 24 weeks＇ treatment, all the patients＇ HBV-DNA ration, HBeAg ration and complement C3 were measured respectively. The patients who were treated for 24 weeks with HBV-DNA ration 〉 5 × 10^2 IU · mL^-1（ poor response） were regarded as the research objects. The control group was treated with the original treatment regimen. The treatment group was treated with Catgut Implantation at the bilateral Zusanti （ST 36 ） on the basis of the original treatment regimen. After 24 weeks, the HBV-DNA, HBeAg and complement C3 in the two groups were measured respectively. Results： After 24 weeks of conventional treatment, the differences in the negative rate of HBV-DNA and HBeAg rate in the two groups were not statistically significant （ P 〉 0.05 ）. After 24 weeks of treatment, the complement C3 of the two groups was higher than that before treatment, but there was no statistical difference between the two groups （P 〉0.05 ）. After 48 weeks＇s treatment, the negative rate sol HBV-DNA and HBeAg and the complement C3 of the treatment group were lower than those of the control group, and the differences were statistically significant （ P 〈 0.05 ）. Conclusion ： For the poor response to Adefovir Dipivoxil Capsules in patients with chronic hepatitis B, Zusanli （ ST 36） catgut embedding therapy can significantly improve the negative rates of HBV-DNA, HBeAg and complement C3, can significantly shorten the course of treatment of patients, and improve the clinical efficacy.